CHAMPS
Conclusion Treated patients experienced a 44% decrease in the rate of developing a second attack when compared to placebo over a three-year period. Based on CHAMPS, the FDA and the European Medicines Evaluation Agency (EMEA) approved Avonex® for first episode MS patients with MRI abnormalities consistent with MS